Diabetes, CKD and SGLT2 Inhibitors

Renal Society of Australasia

Educator: Renal Society of Australasia
Course Duration: 60 minutes

- +


This Webinar will focus on evidence that sodium-glucose-linked cotransport inhibitors (SGLT2i) reduces the development of end-stage kidney disease (ESKD), cardiovascular events, including heart failure and cardiac death in diabetic and non-diabetic patients, with and without chronic kidney disease.

There are no reviews yet.

Be the first to review “Diabetes, CKD and SGLT2 Inhibitors”

Your email address will not be published.